Overview
| Generic Names: | Zonisamida [Spanish]; Zonisamidum [Latin]; zonisamide |
|---|---|
| Trade Names: | Exceglan; Excegram; Excegran; Zonegran |
| PharmGKB Accession Id: | PA451978 |
Description
Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. (source: Drug Bank)
Indication
For use as adjunctive treatment of partial seizures in adults with epilepsy. (source: Drug Bank)
ATC Therapeutic Category
- N03AX:Other antiepileptics
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Zonisamide binds to sodium channels, voltage sensitive calcium channels and to a lesser extent carbonic anhydrase. This blocks or suppresses neuronal depolarization and hypersynchronization. (source: Drug Bank)
Pharmacology
Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium channels which leads to the suppression of neuronal hypersynchronization (i.e. convulsions). Likewise zonisamide has also been found not to potentiate syanptic activity by GABA (gamma amino butyric acid). (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Primarily hepatic through cytochrome P450 isoenzyme 3A4 (CYP3A4). Undergoes acetylation and reduction, forming N-acetyl zonisamide, and the open-ring metabolite 2–sulfamoylacetyl phenol, respectively. (source: Drug Bank)
Protein Binding
40% (at concentrations of 1.0-7.0 µg/mL) (source: Drug Bank)
Absorption
Variable, yet relatively rapid rate of absorption with a time to peak concentration of 2.8-3.9 hours. Food has no effect on the bioavailability of zonisamide. (source: Drug Bank)
Toxicity
Symptoms of overdose include diminished breathing, loss of consciousness, low blood pressure, and slow heartbeat. (source: Drug Bank)
Isomeric SMILES Code:
c1ccc2c(c1)c(no2)CS(=O)(=O)N (source: Drug Bank)
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| CACNA1G |
|
(source: Drug Bank) |
| CA1 |
|
(source: Drug Bank) |
| SCN1A |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Epilepsy |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
